HIV-TriKE

HIV-TriKE is a **preclinical trispecific natural killer cell engager** being developed by GT Biopharma based on technology from the University of Minnesota for potential treatment of **HIV infection**, particularly eradication of latent or persistent viral reservoir cells. It is described as a **single-chain recombinant fusion protein** in the TriKE platform that contains an **anti-CD16 natural killer cell engaging domain**, an **interleukin-15 linker or activating domain** that promotes NK-cell activation and proliferation, and an **HIV-targeting domain directed against HIV envelope antigen on infected CD4 T cells**. In preclinical studies, the construct was reported to enhance NK-cell cytokine production, induce NK-cell proliferation, direct killing of HIV-infected targets, and potentially reactivate and eliminate latent HIV-infected reservoir cells through antibody-directed cellular cytotoxicity-like mechanisms. No approved product name, dosage form, route, or clinical-stage development program has been clearly established for this specific candidate.

Other names

HIV-TriKEHIV TriKEHIV TriKE\u2122